Literature DB >> 2787468

Antibodies to hepatitis B virus x-protein in sera of patients with acute and chronic active hepatitis.

R Abraham1, H W Doerr, W Braun, M Stemler, H Will, G Hess, C H Schröder.   

Abstract

Sera of patients with acute (AH) and chronic active hepatitis (CAH) were tested for anti-hepatitis B virus (HBV) x-protein (HBx) by immunoblotting, using recombinant MS2- and beta gal-HBx fusion proteins as substrate. Antibodies against HBx were detected in 5 out of 17 patients with AH at an early stage of infection, and in 13 out of 35 patients with CAH. Positive sera from AH patients showed a relatively weak anti-HBx reactivity when compared to sera from CAH patients. In follow up studies we tested serial serum samples from patients positive for anti-HBx. Patients with AH were observed for 3 to 6 weeks and CAH patients for up to 51 months. In general anti-HBx reactivities appeared to be stable although significant differences in apparent antibody levels were noted when sera from individual patients were compared. Our data further support an early expression of HBx-antigen in HBV-infected individuals. There was no correlation between HBe-antigen and anti-HBx in CAH.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787468     DOI: 10.1007/bf00202552

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  24 in total

1.  trans-activation of viral enhancers by the hepatitis B virus X protein.

Authors:  D F Spandau; C H Lee
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

2.  Low incidence and high titers of antibodies to hepatitis B virus X-protein in sera of Chinese patients with hepatocellular carcinoma.

Authors:  X H Liang; M Stemler; H Will; R Braun; Z Y Tang; C H Schröder
Journal:  J Med Virol       Date:  1988-07       Impact factor: 2.327

3.  Treatment of hepatitis B surface antigen (HBsAg)-positive chronic hepatitis with recombinant leucocyte alpha-A interferon.

Authors:  G Hess; W Gerlich; J Slusarczyk; T H Hütteroth; K H Meyer zum Büschenfelde
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

4.  Plasmid vectors for high-efficiency expression controlled by the PL promoter of coliphage lambda.

Authors:  E Remaut; P Stanssens; W Fiers
Journal:  Gene       Date:  1981-10       Impact factor: 3.688

5.  Antibodies to peptides detect new hepatitis B antigen: serological correlation with hepatocellular carcinoma.

Authors:  A M Moriarty; H Alexander; R A Lerner; G B Thornton
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

6.  Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus.

Authors:  H Toh; H Hayashida; T Miyata
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

7.  Hepatitis B virus genes and their expression in E. coli.

Authors:  M Pasek; T Goto; W Gilbert; B Zink; H Schaller; P MacKay; G Leadbetter; K Murray
Journal:  Nature       Date:  1979-12-06       Impact factor: 49.962

8.  The conversion of hepatitis B core antigen synthesized in E coli into e antigen.

Authors:  P MacKay; J Lees; K Murray
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

9.  Construction of a new family of high efficiency bacterial expression vectors: identification of cDNA clones coding for human liver proteins.

Authors:  K K Stanley; J P Luzio
Journal:  EMBO J       Date:  1984-06       Impact factor: 11.598

10.  The HBV HBX gene expressed in E. coli is recognised by sera from hepatitis patients.

Authors:  A Kay; E Mandart; C Trepo; F Galibert
Journal:  EMBO J       Date:  1985-05       Impact factor: 11.598

View more
  1 in total

1.  Development of PCR-ELISA for the detection of hepatitis B virus x gene expression and clinical application.

Authors:  Jong-Wan Kim; Jung-Hyun Shim; Joo-Won Park; Won-Cheol Jang; H K Chang; Il Han Song; Sun-Young Baek; Seok-Ho Lee; Do-Young Yoon; Sue-Nie Park
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.